Human Pluripotent Stem Cells for Modeling Toxicity

Advances in Pharmacology

Volumn 63, Issue , 2012, Pages 207-256

  Sison Young, R L C ^a   Kia, R ^a   Heslop, J ^a   Kelly, L ^a   Rowe, C ^a   Cross, M J ^a   Kitteringham, N R ^a   Hanley, N ^a,b   Park, B K ^a   Goldring, C E P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; BUFURALOL; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 1A1; DEXAMETHASONE; HEPATOCYTE NUCLEAR FACTOR 3BETA; MICRORNA; MYOCYTE ENHANCER FACTOR 2; OCTAMER TRANSCRIPTION FACTOR 4; ONCOSTATIN M; RETINOIC ACID; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR SOX17; TRASTUZUMAB; TYROSINE AMINOTRANSFERASE; VERAPAMIL; XENOBIOTIC AGENT;

APOPTOSIS; ARTICLE; ASTROCYTE; CARDIOTOXICITY; CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DENDRITE; DEVELOPMENTAL TOXICITY; DISEASE MODEL; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; ELECTROPHYSIOLOGY; EMBRYO CULTURE; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER TOXICITY; METABOLISM; METABOLOMICS; MICROELECTRODE; MOLECULAR DYNAMICS; MOLECULAR MODEL; MORBIDITY; MORTALITY; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; PLURIPOTENT STEM CELL; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; ROSETTE TEST; STEM CELL RESEARCH; TERATOGENICITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION;

EID: 84863770073     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398339-8.00006-9     Document Type: Chapter

References (279)

1. Adler S., Lindqvist J., Uddenberg K., Hyllner J., Strehl R. Testing potential developmental toxicants with a cytotoxicity assay based on human embryonic stem cells. Alternatives to Laboratory Animals 2008, 36(2):129-140.
2. Adler S., Pellizzer C., Hareng L., Hartung T., Bremer S. First steps in establishing a developmental toxicity test method based on human embryonic stem cells. Toxicology In Vitro 2008, 22(1):200-211.
3. Agarwal S., Holton K.L., Lanza R. Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells 2008, 26(5):1117-1127.
4. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute 2010, 102(1):14-25.
5. Anderson D., Self T., Mellor I.R., Goh G., Hill S.J., Denning C. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Molecular Theraphy 2007, 15(11):2027-2036.
6. Andersson H., Steel D., Asp J., Dahlenborg K., Jonsson M., Jeppsson A., et al. Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells. Journal of Biotechnology 2010, 150(1):175-181.
7. Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., Pachkoria K., García-Ruiz E., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the spanish registry over a 10-year period. Gastroenterology 2005, 129(2):512-521.
8. Anokye-Danso F., Trivedi C.M., Juhr D., Gupta M., Cui Z., Tian Y., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8(4):376-388.
9. Anson B.D., Kolaja K.L., Kamp T.J. Opportunities for use of human iPS cells in predictive toxicology. Clinical Pharmacology & Therapeutics 2011, 89(5):754-758.
10. Aoyama K., Yoshinari K., Kim H.J., Nagata K., Yamazoe Y. Simultaneous expression of plural forms of human cytochrome P450 at desired ratios in HepG2 cells: adenovirus-mediated tool for cytochrome P450 reconstitution. Drug Metabolism and Pharmacokinetics 2009, 24(3):209-217.
11. Baek D.H., Park S.H., Park J.H., Choi Y., Park K.D., Kang J.W., et al. Embryotoxicity of lead (II) acetate and aroclor 1254 using a new end point of the embryonic stem cell test. International Journal of Toxicology 2011, 30(5):498-509.
12. Bahadur G., Morrison M. Patenting human pluripotent cells: balancing commercial, academic and ethical interests. Human Reproduction 2010, 25(1):14-21.
13. Baharvand H., Ashtiani S.K., Valojerdi M.R., Shahverdi A., Taee A., Sabour D. Establishment and in vitro differentiation of a new embryonic stem cell line from human blastocyst. Differentiation 2004, 72(5):224-229.
14. Baharvand H., Hashemi S.M., Ashtiani S.K., Farrokhi A. Differentiation of human embryonic stem cells into hepatocytes in 2D and 3D culture systems in vitro. International Journal of Developmental Biology 2006, 50(7):645-652.
15. Baillie T.A., Rettie A.E. Role of biotransformation in drug-induced toxicity: Influence of intra- and inter-species differences in drug metabolism. Drug Metabolism and Pharmacokinetics 2011, 26(1):15-29.
16. Bar-Nur O., Russ H.A., Efrat S., Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 2011, 9(1):17-23.
17. Barrilleaux B., Knoepfler P.S. Inducing iPSCs to Escape the dish. Cell Stem Cell 2011, 9(2):103-111.
18. Basma H., Soto-Gutiérrez A., Yannam G.R., Liu L., Ito R., Yamamoto T., et al. Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology 2009, 136(3):990-999. e994.
19. Baxter M.A., Rowe C., Alder J., Harrison S., Hanley K.P., Park B.K., et al. Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Research 2010, 5(1):4-22.
20. Beqqali A., Kloots J., Ward-van Oostwaard D., Mummery C., Passier R. Genome-wide transcriptional profiling of human embryonic stem cells differentiating to cardiomyocytes. Stem Cells 2006, 24(8):1956-1967.
21. Bhandari R.N., Riccalton L.A., Lewis A.L., Fry J.R., Hammond A.H., Tendler S.J., et al. Liver tissue engineering: a role for co-culture systems in modifying hepatocyte function and viability. Tissue Engineering 2001, 7(3):345-357.
22. Biedler J.L., Helson L., Spengler B.A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Research 1973, 33(11):2643-2652.
23. Bielby R.C., Boccaccini A.R., Polak J.M., Buttery L.D. In vitro differentiation and in vivo mineralization of osteogenic cells derived from human embryonic stem cells. Tissue Engineering 2004, 10(9, 10):1518-1525.
24. Bigot K., de Lange J., Archer G., Clothier R., Bremer S. The relative semi-quantification of mrna expression as a useful toxicological endpoint for the identification of embryotoxic/teratogenic substances. Toxicology In Vitro 1999, 13(4, 5):619-623.
25. Birrell M.A., Hardaker E., Wong S., McCluskie K., Catley M., De Alba J., et al. I{kappa}-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. American Journal of Respiratory and Critical Care Medicine 2005, 172(8):962-971.
26. Bourdi M., Reilly T.P., Elkahloun A.G., George J.W., Pohl L.R. Macrophage migration inhibitory factor in drug-induced liver injury: a role in susceptibility and stress responsiveness. Biochemical and Biophysical Research Communications 2002, 294(2):225-230.
27. Braam S.R., Tertoolen L., van de Stolpe A., Meyer T., Passier R., Mummery C.L. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Research 2010, 4(2):107-116.
28. Breier J.M., Radio N.M., Mundy W.R., Shafer T.J. Development of a high-throughput screening assay for chemical effects on proliferation and viability of immortalized human neural progenitor cells. Toxicological Sciences 2008, 105(1):119-133.
29. Brolén G., Sivertsson L., Björquist P., Eriksson G., Ek M., Semb H., et al. Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. Journal of Biotechnology 2010, 145(3):284-294.
30. Burridge P.W., Anderson D., Priddle H., Barbadillo Munoz M.D., Chamberlain S., Allegrucci C., et al. Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells 2007, 25(4):929-938.
31. Burridge P.W., Thompson S., Millrod M.A., Weinberg S., Yuan X., Peters A., et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011, 6(4):e18293.
32. Buzanska L., Habich A., Jurga M., Sypecka J., Domanska-Janik K. Human cord blood-derived neural stem cell line - possible implementation in studying neurotoxicity. Toxicology In Vitro 2005, 19(7):991-999.
33. Buzanska L., Sypecka J., Nerini-Molteni S., Compagnoni A., Hogberg H.T., del Torchio R., et al. A human stem cell-based model for identifying adverse effects of organic and inorganic chemicals on the developing nervous system. Stem Cells 2009, 27(10):2591-2601.
34. Cai J., Zhao Y., Liu Y., Ye F., Song Z., Qin H., et al. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 2007, 45(5):1229-1239.
35. Caldwell M.A., He X., Wilkie N., Pollack S., Marshall G., Wafford K.A., et al. Growth factors regulate the survival and fate of cells derived from human neurospheres. Nature Biotechnology 2001, 19(5):475-479.
36. Callihan P., Zitomer N.C., Stoeling M.V., Kennedy P.C., Lynch K.R., Riley R.T., et al. Distinct generation, pharmacology, and distribution of sphingosine 1-phosphate and dihydrosphingosine 1-phosphate in human neural progenitor cells. Neuropharmacology 2011.
37. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.S., Schaniel C., Lee D.F., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465(7299):808-812.
38. Castell J.V., Jover R., Martínez-Jiménez C.P., Gómez-Lechón M.J. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opinion on Drug Metabolism & Toxicology 2006, 2(2):183-212.
39. Celander M.C., Goldstone J.V., Denslow N.D., Iguchi T., Kille P., Meyerhoff R.D., et al. Species extrapolation for the 21st century. Environmental Toxicology and Chemistry 2011, 30(1):52-63.
40. Chen R., Chen J., Cheng S., Qin J., Li W., Zhang L., et al. Assessment of embryotoxicity of compounds in cosmetics by the embryonic stem cell test. Toxicology Mechanisms and Methods 2010, 20(3):112-118.
41. Chen Y.-F., Tseng C.-Y., Wang H.-W., Kuo H.-C., Yang V.W., Lee O.K. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology 2011.
42. Chiao E., Elazar M., Xing Y., Xiong A., Kmet M., Millan M.T., et al. Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cells. Stem Cells 2008, 26(8):2032-2041.
43. Chien K.R. Herceptin and the heart - a molecular modifier of cardiac failure. New England Journal of Medicins 2006, 354(8):789-790.
44. Chung W.S., Shin C.H., Stainier D.Y.R. Bmp2 signaling regulates the hepatic versus pancreatic fate decision. Developmental Cell 2008, 15(5):738-748.
45. Clarkson T.W. The toxicology of mercury. Critical Reviews in Clinical Laboratory Sciences 1997, 34(4):369-403.
46. Colleoni S., Galli C., Gaspar J.A., Meganathan K., Jagtap S., Hescheler J., et al. Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicological Sciences 2011, 124(2):370-377.
47. Cooke A., Harrison D., Skyring A. Use of indocyanine green as a test of liver function. Digestive Diseases and Sciences 1963, 8(3):244-250.
48. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28(40):3526-3536.
49. D'Amour K.A., Agulnick A.D., Eliazer S., Kelly O.G., Kroon E., Baetge E.E. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nature Biotechnology 2005, 23(12):1534-1541.
50. Dash A., Inman W., Hoffmaster K., Sevidal S., Kelly J., Obach R.S., et al. Liver tissue engineering in the evaluation of drug safety. Expert Opinion on Drug Metabolism & Toxicology 2009, 5(10):1159-1174.
51. de Groot D.M., Bos-Kuijpers M.H., Kaufmann W.S., Lammers J.H., O'Callaghan J.P., Pakkenberg B., et al. Regulatory developmental neurotoxicity testing: a model study focussing on conventional neuropathology endpoints and other perspectives. Environmental Toxicology and Pharmacology 2005, 19(3):745-755.
52. de Jong E., Barenys M., Hermsen S.A., Verhoef A., Ossendorp B.C., Bessems J.G., et al. Comparison of the mouse embryonic stem cell test, the rat whole embryo culture and the zebrafish embryotoxicity test as alternative methods for developmental toxicity testing of six 1,2,4-triazoles. Toxicology and Applied Pharmacology 2011, 253(2):103-111.
53. De Smedt A., Steemans M., De Boeck M., Peters A.K., van der Leede B.J., Van Goethem F., et al. Optimisation of the cell cultivation methods in the embryonic stem cell test results in an increased differentiation potential of the cells into strong beating myocard cells. Toxicology In Vitro 2008, 22(7):1789-1796.
54. Di Guglielmo C., Lopez D.R., De Lapuente J., Mallafre J.M., Suarez M.B. Embryotoxicity of cobalt ferrite and gold nanoparticles: a first in vitro approach. Reproductive Toxicology 2010, 30(2):271-276.
55. Dick E., Rajamohan D., Ronksley J., Denning C. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochemical Society Transactions 2010, 38(4):1037-1045.
56. Dolci A., Dominici R., Cardinale D., Sandri M.T., Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. American Journal of Clinical Pathology 2008, 130(5):688-695.
57. Duan Y., Catana A., Meng Y., Yamamoto N., He S., Gupta S., et al. Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo. Stem Cells 2007, 25(12):3058-3068.
58. Duan Y., Ma X., Zou W.E.I., Wang C., Bahbahan I.S., Ahuja T.P., et al. Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells. Stem Cells 2010, 28(4):674-686.
59. Duanmu Z., Locke D., Smigelski J., Wu W., Dahn M.S., Falany C.N., et al. Effects of dexamethasone on aryl (SULT1A1)- and hydroxysteroid (SULT2A1)-sulfotransferase gene expression in primary cultured human hepatocytes. Drug Metabolism and Disposition 2002, 30(9):997-1004.
60. Dubois N.C., Craft A.M., Sharma P., Elliott D.A., Stanley E.G., Elefanty A.G., et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nature Biotechnology 2011.
61. Eberhard D., O'Neill K., Burke Z.D., Tosh D. In vitro reprogramming of pancreatic cells to hepatocytes. Methods in Molecular Biology 2010, 636:285-292.
62. EC1907/2006.
63. Eckardt K., Stahlmann R. Use of two validated in vitro tests to assess the embryotoxic potential of mycophenolic acid. Archives in Toxicology 2010, 84(1):37-43.
64. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356(9237):1255-1259.
65. Ek M., Söderdahl T., Küppers-Munther B., Edsbagge J., Andersson T.B., Björquist P., et al. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochemical Pharmacology 2007, 74(3):496-503.
66. Elaut G., Henkens T., Papeleu P., Snykers S., Vinken M., Vanhaecke T., et al. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Current Drug Metabolism 2006, 7(6):629-660.
67. Elsaesser A., Howard C.V. Toxicology of nanoparticles. Advanced Drug Delivery Reviews 2011.
68. Espandiari P., Rosenzweig B., Zhang J., Zhou Y., Schnackenberg L., Vaidya V.S., et al. Age-related differences in susceptibility to cisplatin-induced renal toxicity. Journal of Applied Toxicology 2010, 30(2):172-182.
69. Eugenin E.A., King J.E., Hazleton J.E., Major E.O., Bennett M.V., Zukin R.S., et al. Differences in NMDA receptor expression during human development determine the response of neurons to HIV-tat-mediated neurotoxicity. Neurotoxicological Research 2011, 19(1):138-148.
70. Fair J.H., Cairns B.A., LaPaglia M., Wang J., Meyer A.A., Kim H., et al. Induction of hepatic differentiation in embryonic stem cells by co-culture with embryonic cardiac mesoderm. Surgery 2003, 134(2):189-196.
71. Fausto N. Liver regeneration. Journal of Hepatology 2000, 32(1 Suppl.):19-31.
72. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews Drug Discovery 2003, 2(6):439-447.
73. Fleischer M. Testing costs and testing capacity according to the REACH requirements - results of a survey of independent and corporate GLP laboratories in the EU and Switzerland. Journal of Business Chemistry 2007, 4(3):96-114.
74. Flick B., Klug S. Whole embryo culture: an important tool in developmental toxicology today. Current Pharmaceutical Design 2006, 12(12):1467-1488.
75. Flint O.P., Orton T.C., Ferguson R.A. Differentiation of rat embryo cells in culture: response following acute maternal exposure to teratogens and non-teratogens. J Appl Toxicol 1984, 4(2):109-116.
76. Fritsche E., Cline J.E., Nguyen N.H., Scanlan T.S., Abel J. Polychlorinated biphenyls disturb differentiation of normal human neural progenitor cells: clue for involvement of thyroid hormone receptors. Environmental Health Perspectives 2005, 113(7):871-876.
77. Gachon F., Firsov D. The role of circadian timing system on drug metabolism and detoxification. Expert Opinion on Drug Metabolism & Toxicology 2011, 7(2):147-158.
78. Genschow E., Scholz G., Brown N., Piersma A., Brady M., Clemann N., et al. Development of prediction models for three in vitro embryotoxicity tests in an ECVAM validation study. In Vitro and Molecular Toxicology 2000, 13(1):51-66.
79. Genschow E., Spielmann H., Scholz G., Seiler A., Brown N., Piersma A., et al. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Alternatives to Laboratory Animals 2002, 30(2):151-176.
80. Genschow E., Spielmann H., Scholz G., Pohl I., Seiler A., Clemann N., et al. Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. Alternatives to Laboratory Animals 2004, 32(3):209-244.
81. Ghodsizadeh A., Taei A., Totonchi M., Seifinejad A., Gourabi H., Pournasr B., et al. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Reviews and Reports 2010, 6(4):622-632.
82. Gokhale M., Martin B.C. Prescription-acquired acetaminophen use and potential overuse patterns: 2001-2008. Pharmacoepidemiology and Drug Safety 2011.
83. Goldring C.E.P., Kitteringham N.R., Elsby R., Randle L.E., Clement Y.N., Williams D.P., et al. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 2004, 39(5):1267-1276.
84. Goldring C.E.P., Kitteringham N.R., Jenkins R., Lovatt C.A., Randle L.E., Abdullah A., et al. Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. American Journal of Physiology - Cell Physiology 2006, 290(1):C104-C115.
85. González F., Boué S., Belmonte J.C.I. Methods for making induced pluripotent stem cells: Reprogramming à la carte. Nature Reviews Genetics 2011, 12(4):231-242.
86. Gouon-Evans V., Boussemart L., Gadue P., Nierhoff D., Koehler C.I., Kubo A., et al. BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. Nature Biotechnology 2006, 24(11):1402-1411.
87. Graichen R., Xu X., Braam S.R., Balakrishnan T., Norfiza S., Sieh S., et al. Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation 2008, 76(4):357-370.
88. Greenlee A.R., Kronenwetter-Koepel T.A., Kaiser S.J., Liu K. Comparison of Matrigel and gelatin substrata for feeder-free culture of undifferentiated mouse embryonic stem cells for toxicity testing. Toxicology In Vitro 2005, 19(3):389-397.
89. Groebe K., Hayess K., Klemm-Manns M., Schwall G., Wozny W., Steemans M., et al. Protein biomarkers for in vitro testing of embryotoxicity. Journal of Proteome Research 2010, 9(11):5727-5738.
90. Groebe K., Hayess K., Klemm-Manns M., Schwall G., Wozny W., Steemans M., et al. Unexpected common mechanistic pathways for embryotoxicity of warfarin and lovastatin. Reproductive Toxicology 2010, 30(1):121-130.
91. Guguen-Guillouzo C., Guillouzo A. General review on in vitro hepatocyte models and their applications. Methods in Molecular Biology 2010, 640:1-40.
92. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., et al. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicological Sciences 2011, 123(1):281-289.
93. Hafner M., Landthaler M., Burger L., Khorshid M., Hausser J., Berninger P., et al. Transcriptome-wide Identification of RNA-binding protein and MicroRNA target sites by PAR-CLIP. Cell 2010, 141(1):129-141.
94. Hamazaki T., Iiboshi Y., Oka M., Papst P.J., Meacham A.M., Zon L.I., et al. Hepatic maturation in differentiating embryonic stem cells in vitro. FEBS Letters 2001, 497(1):15-19.
95. Han Y., Miller A., Mangada J., Liu Y., Swistowski A., Zhan M., et al. Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One 2009, 4(9):e7155.
96. Hang H.L., Zhang L., Shi X.L., Bian J.M., Ding Y.T. Isolation, culture and cryopreservation of adult human hepatocytes. World Chinese Journal of Digestology 2011, 19(19):2016-2021.
97. Hareng L., Pellizzer C., Bremer S., Schwarz M., Hartung T. The integrated project ReProTect: a novel approach in reproductive toxicity hazard assessment. Reproductive Toxicology 2005, 20(3):441-452.
98. Harrill J.A., Freudenrich T.M., Machacek D.W., Stice S.L., Mundy W.R. Quantitative assessment of neurite outgrowth in human embryonic stem cell-derived hN2 cells using automated high-content image analysis. Neurotoxicology 2010, 31(3):277-290.
99. Hartung T., Rovida C. Chemical regulators have overreached. Nature 2009, 460(7259):1080-1081.
100. Hattori F., Chen H., Yamashita H., Tohyama S., Satoh Y.S., Yuasa S., et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nature Methods 2010, 7(1):61-66.
101. Hay D.C., Fletcher J., Payne C., Terrace J.D., Gallagher R.C.J., Snoeys J., et al. Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(34):12,301-12,306.
102. He J.Q., Ma Y., Lee Y., Thomson J.A., Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circulation Research 2003, 93(1):32-39.
103. Hettwer M., Reis-Fernandes M.A., Iken M., Ott M., Steinberg P., Nau H. Metabolic activation capacity by primary hepatocytes expands the applicability of the embryonic stem cell test as alternative to experimental animal testing. Reproductive Toxicology 2010, 30(1):113-120.
104. Hofer T., Gerner I., Gundert-Remy U., Liebsch M., Schulte A., Spielmann H., et al. Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Archives in Toxicology 2004, 78(10):549-564.
105. Hoffman R.M. To do tissue culture in two or three dimensions? That is the question. Stem Cells 1993, 11(2):105-111.
106. Honda M., Kiyokawa J., Tabo M., Inoue T. Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. Journal of Pharmacological Sciences 2011.
107. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nature Biotechnology 2008, 26(11):1269-1275.
108. Imai K., Nakamura M. In vitro embryotoxicity testing of metals for dental use by differentiation of embryonic stem cell test. Congenital Anomaly (Kyoto) 2006, 46(1):34-38.
109. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology and Therapeutics 2007, 116(3):496-526.
110. Ishii T., Fukumitsu K., Yasuchika K., Adachi K., Kawase E., Suemori H., et al. Effects of extracellular matrixes and growth factors on the hepatic differentiation of human embryonic stem cells. American Journal of Physiology - Gastrointestinal and Liver Physiology 2008, 295(2):G313-G321.
111. Itoh K., Igarashi K., Hayashi N., Nishizawa M., Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Molecular and Cellular Biology 1995, 15(8):4184-4193.
112. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and Biophysical Research Communications 1997, 236(2):313-322.
113. Itskovitz-Eldor J., Schuldiner M., Karsenti D., Eden A., Yanuka O., Amit M., et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Molecular Medicine 2000, 6(2):88-95.
114. Jagtap S., Meganathan K., Gaspar J., Wagh V., Winkler J., Hescheler J., et al. Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. British Journal of Pharmacology 2011, 162(8):1743-1756.
115. Johnson G. Lithium - early development, toxicity, and renal function. Neuropsychopharmacology 1998, 19(3):200-205.
116. Jozefczuk J., Prigione A., Chavez L., Adjaye J. Comparative analysis of human embryonic stem cell and induced pluripotent stem cell-derived hepatocyte-like cells reveals current drawbacks and possible strategies for improved differentiation. Stem Cells and Development 2011, 20(7):1259-1275.
117. Kamiya A., Kinoshita T., Miyajima A. Oncostatin M and hepatocyte growth factor induce hepatic maturation via distinct signaling pathways. FEBS Letters 2001, 492(1, 2):90-94.
118. Kang K.S., Park J.E., Ryu D.Y., Lee Y.S. Effects and neuro-toxic mechanisms of 2, 2', 4, 4', 5, 5'-hexachlorobiphenyl and endosulfan in neuronal stem cells. Journal of Veterinary Medical Science 2001, 63(11):1183-1190.
119. Kang Y.H., Berthiaume F., Nath B.D., Yarmush M.L. Growth factors and nonparenchymal cell conditioned media induce mitogenic responses in stable long-term adult rat hepatocyte cultures. Experimental Cell Research 2004, 293(2):239-247.
120. Karginov F.V., Conaco C., Xuan Z., Schmidt B.H., Parker J.S., Mandel G., et al. A biochemical approach to identifying microRNA targets. Proceedings of the National Academy of Sciences 2007, 104(49):19,291-19,296.
121. Kehat I., Kenyagin-Karsenti D., Snir M., Segev H., Amit M., Gepstein A., et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. Journal of Clinical Investigations 2001, 108(3):407-414.
122. Kettenhofen R., Bohlen H. Preclinical assessment of cardiac toxicity. Drug Discovery Today 2008, 13(15, 16):702-707.
123. Khetani S.R., Bhatia S.N. Microscale culture of human liver cells for drug development. Nature Biotechnology 2008, 26(1):120-126.
124. Kidambi S., Sheng L., Yarmush M.L., Toner M., Lee I., Chan C. Patterned co-culture of primary hepatocytes and fibroblasts using polyelectrolyte multilayer templates. Macromolecular Bioscience 2007, 7(3):344-353.
125. Kim N., Kim H., Jung I., Kim Y., Kim D., Han Y.-M. Expression profiles of miRNAs in human embryonic stem cells during hepatocyte differentiation. Hepatology Research 2011, 41(2):170-183.
126. Kleinstreuer N.C., Smith A.M., West P.R., Conard K.R., Fontaine B.R., Weir-Hauptman A.M., et al. Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicology and Applied Pharmacology 2011, 257(1):111-121.
127. Kubo A., Shinozaki K., Shannon J.M., Kouskoff V., Kennedy M., Woo S., et al. Development of definitive endoderm from embryonic stem cells in culture. Development 2004, 131(7):1651-1662.
128. Kusuda Furue M., Tateyama D., Kinehara M., Na J., Okamoto T., Sato J.D. Advantages and difficulties in culturing human pluripotent stem cells in growth factor-defined serum-free medium. In Vitro Cellular & Developmental Biology - Animal 2010, 46(7):573-576.
129. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294(5543):853-858.
130. Laposa R.R. Stem cells for drug screening. Journal of Cardiovascular Pharmacology 2011, 58(3):240-245.
131. Lappalainen R.S., Salomaki M., Yla-Outinen L., Heikkila T.J., Hyttinen J.A., Pihlajamaki H., et al. Similarly derived and cultured hESC lines show variation in their developmental potential towards neuronal cells in long-term culture. Regenerative Medicine 2010, 5(5):749-762.
132. Laudadio I., Manfroid I., Achouri Y., Schmidt D., Wilson M.D., Cordi S., et al. A feedback loop between the liver-enriched transcription factor network and Mir-122 controls hepatocyte differentiation. Gastroenterology 2011.
133. Laurent L.C., Ulitsky I., Slavin I., Tran H., Schork A., Morey R., et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011, 8(1):106-118.
134. Lavon N., Benvenisty N. Study of hepatocyte differentiation using embryonic stem cells. Journal of Cellular Biochemistry 2005, 96(6):1193-1202.
135. Lavon N., Yanuka O., Benvenisty N. Differentiation and isolation of hepatic-like cells from human embryonic stem cells. Differentiation 2004, 72(5):230-238.
136. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. JAMA: The Journal of the American Medical Association 1998, 279(15):1200-1205.
137. Lee W.M. Acute liver failure in the United States. Seminal Liver Disease 2003, 23(03):217,226.
138. Lee E.W., Lai Y., Zhang H., Unadkat J.D. Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. Journal of Biological Chemistry 2006, 281(24):16,700-16,706.
139. Lee N., Authier S., Pugsley M.K., Curtis M.J. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?. Toxicology and Applied Pharmacology 2010, 243(2):146-153.
140. Li S.S.-L., Yu S.-L., Kao L.-P., Tsai Z.Y., Singh S., Chen B.Z., et al. Target identification of microRNAs expressed highly in human embryonic stem cells. Journal of Cellular Biochemistry 2009, 106(6):1020-1030.
141. Li Z.-Y., Xi Y., Zhu W.-N., Zeng C., Zhang Z.-Q., Guo Z.-C., et al. Positive regulation of hepatic miR-122 expression by HNF4α. Journal of Hepatology 2011, 55(3):602-611.
142. Liao B., Bao X., Liu L., Feng S., Zovoilis A., Liu W., et al. MicroRNA cluster 302-367 enhances somatic cell reprogramming by accelerating a mesenchymal-to-epithelial transition. Journal of Biological Chemistry 2011, 286(19):17,359-17,364.
143. Lin S.-L. Deciphering the mechanism behind iPSC generation. Stem Cells 2011.
144. Lin S., Talbot P. Methods for culturing mouse and human embryonic stem cells. Methods in Molecular Biology 2011, 690:31-56.
145. Lin S.L., Chang D.C., Lin C.H., Ying S.Y., Leu D., Wu D.T.S. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Research 2011, 39(3):1054-1065.
146. Lister R., Pelizzola M., Kida Y.S., Hawkins R.D., Nery J.R., Hon G., et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471(7336):68-73.
147. LoPachin R.M. The changing view of acrylamide neurotoxicity. Neurotoxicology 2004, 25(4):617-630.
148. Lumelsky N., Blondel O., Laeng P., Velasco I., Ravin R., McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 2001, 292(5520):1389-1394.
149. Luyendyk J.P., Maddox J.F., Cosma G.N., Ganey P.E., Cockerell G.L., Roth R.A. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. Journal of Pharmacology and Experimental Therapeutics 2003, 307(1):9-16.
150. Maddrey W.C. Drug-induced hepatotoxicity: 2005. Journal of Clinical Gastroenterology 2005, 39(4 Suppl 2):S83-S89.
151. Marro S., Pang Z.P., Yang N., Tsai M.C., Qu K., Chang H.Y., et al. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell Stem Cell 2011, 9(4):374-382.
152. Marx-Stoelting P., Adriaens E., Ahr H.J., Bremer S., Garthoff B., Gelbke H.P., et al. A review of the implementation of the embryonic stem cell test (EST). The report and recommendations of an ECVAM/ReProTect Workshop. Alternatives to Laboratory Animals 2009, 37(3):313-328.
153. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., Staniforth A., et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. European Heart Journal 2011, 32(8):952-962.
154. McLean A.B., D'Amour K.A., Jones K.L., Krishnamoorthy M., Kulik M.J., Reynolds D.M., et al. Activin A efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells 2007, 25(1):29-38.
155. Meamar R., Karamali F., Sadeghi H.M., Etebari M., Nasr-Esfahani M.H., Baharvand H. Toxicity of ecstasy (MDMA) towards embryonic stem cell-derived cardiac and neural cells. Toxicology In Vitro 2010, 24(4):1133-1138.
156. Meyer T., Leisgen C., Gonser B., Gunther E. QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay and Drug Development Technologies 2004, 2(5):507-514.
157. Misiuta I.E., Saporta S., Sanberg P.R., Zigova T., Willing A.E. Influence of retinoic acid and lithium on proliferation and dopaminergic potential of human NT2 cells. Journal of Neuroscience Research 2006, 83(4):668-679.
158. Mitchell S.J., Kane A.E., Hilmer S.N. Age-related changes in the hepatic pharmacology and toxicology of paracetamol. Current Gerontology and Geriatrics Research 2011, 2011:624,156.
159. Miyoshi N., Ishii H., Nagano H., Haraguchi N., Dewi D.L., Kano Y., et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011, 8(6):633-638.
160. Momose Y., Matsunaga T., Murai K., Takezawa T., Ohmori S. Differentiation of monkey embryonic stem cells into hepatocytes and mRNA expression of cytochrome P450 enzymes responsible for drug metabolism: Comparison of embryoid body formation conditions and matrices. Biological and Pharmaceutical Bulletin 2009, 32(4):619-626.
161. Moore R.N., Moghe P.V. Expedited growth factor-mediated specification of human embryonic stem cells toward the hepatic lineage. Stem Cell Research 2009, 3(1):51-62.
162. Moretti A., Bellin M., Jung C.B., Thies T.M., Takashima Y., Bernshausen A., et al. Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB Journal 2010, 24(3):700-711.
163. Mummery C. Sorting cardiomyocytes: a simple solution after all?. Nature Methods 2010, 7(1):40-42.
164. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107(21):2733-2740.
165. Mummery C.L., Ward D., Passier R. Differentiation of human embryonic stem cells to cardiomyocytes by coculture with endoderm in serum-free medium. Current Protocols in Stem Cell Biology 2007, Chapter 1, Unit 1F 2.
166. Nakanishi M., Kurisaki A., Hayashi Y., Warashina M., Ishiura S., Kusuda-Furue M., et al. Directed induction of anterior and posterior primitive streak by Wnt from embryonic stem cells cultured in a chemically defined serum-free medium. FASEB Journal 2009, 23(1):114-122.
167. Ndountse L.T., Chan H.M. Methylmercury increases N-methyl-d-aspartate receptors on human SH-SY 5Y neuroblastoma cells leading to neurotoxicity. Toxicology 2008, 249(2, 3):251-255.
168. Nicolson T.J., Mellor H.R., Roberts R.R. Gender differences in drug toxicity. Trends in Pharmacological Sciences 2010, 31(3):108-114.
169. OECD. Guidelines for the testing of chemicals.
170. Ohi Y., Qin H., Hong C., Blouin L., Polo J.M., Guo T., et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nature Cell Biology 2011, 13(5):541-549.
171. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 2000, 32(1):56-67.
172. Osman A.M., van Dartel D.A., Zwart E., Blokland M., Pennings J.L., Piersma A.H. Proteome profiling of mouse embryonic stem cells to define markers for cell differentiation and embryotoxicity. Reproductive Toxicology 2010, 30(2):322-332.
173. Paquette J.A., Kumpf S.W., Streck R.D., Thomson J.J., Chapin R.E., Stedman D.B. Assessment of the Embryonic Stem Cell Test and application and use in the pharmaceutical industry. Birth Defects Research: Part B, Developmental and Reproductive Toxicology 2008, 83(2):104-111.
174. Park B.K., Kitteringham N.R., Pirmohamed M., Tucker G.T. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. British Journal of Clinical Pharmacology 1996, 41(6):477-491.
175. Park B.K., Kitteringham N.R., Maggs J.L., Pirmohamed M., Williams D.P. The role of metabolic activation in drug-induced hepatotoxicity. Annual Review of Pharmacology and Toxicology 2005, 45:177-202.
176. Park H.R., Kim M.S., Kim S.J., Park M., Kong K.H., Kim H.S., et al. Acrylamide induces cell death in neural progenitor cells and impairs hippocampal neurogenesis. Toxicological Letters 2010, 193(1):86-93.
177. Pei H., Yang Y., Xi J., Bai Z., Yue W., Nan X., et al. Lineage restriction and differentiation of human embryonic stem cells into hepatic progenitors and zone 1 hepatocytes. Tissue Engineering - Part C: Methods 2009, 15(1):95-104.
178. Pellizzer C., Adler S., Corvi R., Hartung T., Bremer S. Monitoring of teratogenic effects in vitro by analysing a selected gene expression pattern. Toxicology In Vitro 2004, 18(3):325-335.
179. Peran M., Sanchez-Ferrero A., Tosh D., Marchal J.A., Lopez E., Alvarez P., et al. Ultrastructural and molecular analyzes of insulin-producing cells induced from human hepatoma cells. Cytotherapy 2011, 13(2):193-200.
180. Peters A.K., Wouwer G.V., Weyn B., Verheyen G.R., Vanparys P., Gompel J.V. Automated analysis of contractility in the embryonic stem cell test, a novel approach to assess embryotoxicity. Toxicology In Vitro 2008, 22(8):1948-1956.
181. Pfaff N., Fiedler J., Holzmann A., Schambach A., Moritz T., Cantz T., et al. miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. EMBO Reports 2011, 12(11):1153-1159.
182. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 2001, 276(39):36,734-36,741.
183. Pick M., Stelzer Y., Bar-Nur O., Mayshar Y., Eden A., Benvenisty N. Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. Stem Cells 2009, 27(11):2686-2690.
184. Piersma A.H. Alternative methods for developmental toxicity testing. Basic & Clinical Pharmacology & Toxicology 2006, 98(5):427-431.
185. Piersma A.H., Genschow E., Verhoef A., Spanjersberg M.Q., Brown N.A., Brady M., et al. Validation of the postimplantation rat whole-embryo culture test in the international ECVAM validation study on three in vitro embryotoxicity tests. Alternatives to Laboratory Animals 2004, 32(3):275-307.
186. Pirmohamed M., James S., Meakin S., Green C., Scott A.K., Walley T.J., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004, 329(7456):15-19.
187. Podolin P.L., Callahan J.F., Bolognese B.J., Li Y.H., Carlson K., Davis T.G., et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. Journal of Pharmacology and Experimental Therapeutics 2005, 312(1):373-381.
188. Polo J.M., Liu S., Figueroa M.E., Kulalert W., Eminli S., Tan K.Y., et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nature Biotechnology 2010, 28(8):848-855.
189. Ponsoda X., Pareja E., Gómez-Lechón M.J., Fabra R., Carrasco E., Trullenque R., et al. Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. Journal of Hepatology 2001, 34(1):19-25.
190. Pouton C.W., Haynes J.M. Embryonic stem cells as a source of models for drug discovery. Nature Reviews Drug Discovery 2007, 6(8):605-616.
191. Prescott C. The business of exploiting induced pluripotent stem cells. Philosophical Transactions of the Royal Society B: Biological Sciences 2011, 366(1575):2323-2328.
192. Rashid S.T., Corbineau S., Hannan N., Marciniak S.J., Miranda E., Alexander G., et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. The Journal of Clinical Investigation 2010, 120(9):3127-3136.
193. Renaud H.J., Cui J.Y., Khan M., Klaassen C.D. Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicological Sciences 2011, 124(2):261-277.
194. Romero A.C., Vilanova E., Sogorb M.A. Shortening and improving the embryonic stem cell test through the use of gene biomarkers of differentiation. Journal of Toxicology 2011, 2011:286,034.
195. Roskelley C.D., Desprez P.Y., Bissell M.J. Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(26):12,378-12,382.
196. Roth R.A., Ganey P.E. Intrinsic versus idiosyncratic drug-induced hepatotoxicity - two villains or one?. Journal of Pharmacology and Experimental Therapeutics 2010, 332(3):692-697.
197. Rust W., Balakrishnan T., Zweigerdt R. Cardiomyocyte enrichment from human embryonic stem cell cultures by selection of ALCAM surface expression. Regenerative Medicine 2009, 4(2):225-237.
198. Saez-Rodriguez J., Alexopoulos L.G., Zhang M., Morris M.K., Lauffenburger D.A., Sorger P.K. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Research 2011, 71(16):5400-5411.
199. Saldana-Ruiz S., Soler-Martin C., Llorens J. Role of CYP2E1-mediated metabolism in the acute and vestibular toxicities of nineteen nitriles in the mouse. Toxicological Letters 2011.
200. Salerno S., Campana C., Morelli S., Drioli E., De Bartolo L. Human hepatocytes and endothelial cells in organotypic membrane systems. Biomaterials 2011, 32(34):8848-8859.
201. Sarafian T., Verity M.A. Oxidative mechanisms underlying methyl mercury neurotoxicity. International Journal of Developmental Neuroscience 1991, 9(2):147-153.
202. Sartiani L., Bettiol E., Stillitano F., Mugelli A., Cerbai E., Jaconi M.E. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 2007, 25(5):1136-1144.
203. Satin J., Kehat I., Caspi O., Huber I., Arbel G., Itzhaki I., et al. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. Journal of Physiology 2004, 559(Pt 2):479-496.
204. Satin J., Itzhaki I., Rapoport S., Schroder E.A., Izu L., Arbel G., et al. Calcium handling in human embryonic stem cell-derived cardiomyocytes. Stem Cells 2008, 26(8):1961-1972.
205. Schmidt M.M., Guan K., Wobus A.M. Lithium influences differentiation and tissue-specific gene expression of mouse embryonic stem (ES) cells in vitro. International Journal of Developmental Biology 2001, 45(2):421-429.
206. Schwartz C.M., Spivak C.E., Baker S.C., McDaniel T.K., Loring J.F., Nguyen C., et al. NTera2: a model system to study dopaminergic differentiation of human embryonic stem cells. Stem Cells and Development 2005, 14(5):517-534.
207. Schwengberg S., Bohlen H., Kleinsasser N., Kehe K., Seiss M., Walther U.I., et al. In vitro embryotoxicity assessment with dental restorative materials. Journal of Dentistry 2005, 33(1):49-55.
208. Seiler A.E., Spielmann H. The validated embryonic stem cell test to predict embryotoxicity in vitro. Nature Protocols 2011, 6(7):961-978.
209. Shen C.N., Tosh D. Transdifferentiation of pancreatic cells to hepatocytes. Methods in Molecular Biology 2010, 640:273-280.
210. Shirahashi H., Wu J., Yamamoto N., Catana A., Wege H., Wager B., et al. Differentiation of human and mouse embryonic stem cells along a hepatocyte lineage. Cell Transplantation 2004, 13(3):197-211.
211. Shiraki N., Umeda K., Sakashita N., Takeya M., Kume K., Kume S. Differentiation of mouse and human embryonic stem cells into hepatic lineages. Genes to Cells 2008, 13(7):731-746.
212. Si-Tayeb K., Noto F.K., Nagaoka M., Li J., Battle M.A., Duris C., et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010, 51(1):297-305.
213. Singh S., Kumar V., Singh P., Banerjee B.D., Rautela R.S., Grover S.S., et al. Influence of CYP2C9, GSTM1, GSTT1 and NAT2 genetic polymorphisms on DNA damage in workers occupationally exposed to organophosphate pesticides. Mutation Research 2011.
214. Skrzypiec-Spring M., Grotthus B., Szelag A., Schulz R. Isolated heart perfusion according to Langendorff - still viable in the new millennium. Journal of Pharmacological and Toxicological Methods 2007, 55(2):113-126.
215. Smith D.A., Schmid E.F. Drug withdrawals and the lessons within. Current Opinion in Drug Discovery & Development 2006, 9(1):38-46.
216. Snir M., Kehat I., Gepstein A., Coleman R., Itskovitz-Eldor J., Livne E., et al. Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology 2003, 285(6):H2355-H2363.
217. Snykers S., De Kock J., Rogiers V., Vanhaecke T. In vitro differentiation of embryonic and adult stem cells into hepatocytes: state of the art. Stem Cells 2009, 27(3):577-605.
218. Söderdahl T., Küppers-Munther B., Heins N., Edsbagge J., Björquist P., Cotgreave I., et al. Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells. Toxicology in Vitro 2007, 21(5):929-937.
219. Song Z., Cai J., Liu Y., Zhao D., Yong J., Duo S., et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Research 2009, 19(11):1233-1242.
220. Soto-Gutiérrez A., Kobayashi N., Rivas-Carrillo J.D., Navarro-álvarez N., Zhao D., Okitsu T., et al. Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nature Biotechnology 2006, 24(11):1412-1419.
221. Soto-Gutierrez A., Navarro-Alvarez N., Zhao D., Rivas-Carrillo J.D., Lebkowski J., Tanaka N., et al. Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. Nature Protocols 2007, 2(2):347-356.
222. Spielmann H. Predicting the risk of developmental toxicity from in vitro assays. Toxicology and Applied Pharmacology 2005, 207(2 Suppl.):375-380.
223. Spielmann H., Vogel R. REACH testing requirements must not be driven by reproductive toxicity testing. Alternative to Laboratory Animals 2006, 34(4):365-366.
224. Spielmann H., Pohl I., Doring B., Liebsch M., Moldenhauer F. The embryonic stem cells test (EST), an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embyronic stem cells. In Vitro Toxicology 1997, 10:119-127.
225. Stadtfeld M., Apostolou E., Akutsu H., Fukuda A., Follett P., Natesan S., et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010, 465(7295):175-181.
226. Stummann T.C., Hareng L., Bremer S. Hazard assessment of methylmercury toxicity to neuronal induction in embryogenesis using human embryonic stem cells. Toxicology 2009, 257(3):117-126.
227. Subramanyam D., Lamouille S., Judson R.L., Liu J.Y., Bucay N., Derynck R., et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nature Biotechnology 2011, 29(5):443-448.
228. Sudakin D.L., Stone D.L. Dialkyl phosphates as biomarkers of organophosphates: the current divide between epidemiology and clinical toxicology. Clinical Toxicology (Philadelphia) 2011, 49(9):771-781.
229. Sullivan G.J., Hay D.C., Park I.-H., Fletcher J., Hannoun Z., Payne C.M., et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010, 51(1):329-335.
230. Suzuki N., Ando S., Sumida K., Horie N., Saito K. Analysis of altered gene expression specific to embryotoxic chemical treatment during embryonic stem cell differentiation into myocardiac and neural cells. Journal of Toxicological Sciences 2011, 36(5):569-585.
231. Tada H., Shiho O., Kuroshima K., Koyama M., Tsukamoto K. An improved colorimetric assay for interleukin 2. Journal of Immunological Methods 1986, 93(2):157-165.
232. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
233. Tan S., Guo J., Huang Q., Chen X., Li-Ling J., Li Q., et al. Retained introns increase putative microRNA targets within 3' UTRs of human mRNA. FEBS Letters 2007, 581(6):1081-1086.
234. Tanimizu N., Miyajima A. Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. Journal of Cell Science 2004, 117(15):3165-3174.
235. Tekin D., Kayaalti Z., Soylemezoglu T. The effects of metallothionein 2A polymorphism on lead metabolism: are pregnant women with a heterozygote genotype for metallothionein 2A polymorphism and their newborns at risk of having higher blood lead levels?. International Archives of Occupational and Environmental Health 2011.
236. Terrar D.A., Wilson C.M., Graham S.G., Bryant S.M., Heath B.M. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. Journal of Pharmacological and Toxicological Methods 2007, 56(2):171-185.
237. The International Conference on Harmonisation. (2011). Safety Guidelines. Available from: (retrieved 26 October 2011). http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
238. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282(5391):1145-1147.
239. Tian X.Y., Xu M., Deng B., Leung K.S., Cheng K.F., Zhao Z.Z., et al. The effects of Boehmeria nivea (L.) Gaud. on embryonic development: in vivo and in vitro studies. Journal of Ethnopharmacology 2011, 134(2):393-398.
240. Tohse N., Seki S., Kobayashi T., Tsutsuura M., Nagashima M., Yamada Y. Development of excitation-contraction coupling in cardiomyocytes. The Japanese Journal of Physiology 2004, 54(1):1-6.
241. Topol E.J. Failing the public health-rofecoxib, Merck, and the FDA. New England Journal of Medicine 2004, 351(17):1707-1709.
242. Touboul T., Hannan N.R.F., Corbineau S., Martinez A., Martinet C., Branchereau S., et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 2010, 51(5):1754-1765.
243. Ungrin M.D., Joshi C., Nica A., Bauwens C., Zandstra P.W. Reproducible, ultra high-throughput formation of multicellular organization from single cell suspension-derived human embryonic stem cell aggregates. PLoS One 2008, 3(2):e1565.
244. Uyama N., Shimahara Y., Kawada N., Seki S., Okuyama H., Iimuro Y., et al. Regulation of cultured rat hepatocyte proliferation by stellate cells. Journal of Hepatology 2002, 36(5):590-599.
245. van Dartel D.A., Zeijen N.J., de la Fonteyne L.J., van Schooten F.J., Piersma A.H. Disentangling cellular proliferation and differentiation in the embryonic stem cell test, and its impact on the experimental protocol. Reproductive Toxicology 2009, 28(2):254-261.
246. van Dartel D.A., Pennings J.L., de la Fonteyne L.J., Brauers K.J., Claessen S., van Delft J.H., et al. Evaluation of developmental toxicant identification using gene expression profiling in embryonic stem cell differentiation cultures. Toxicological Sciences 2011, 119(1):126-134.
247. van der Jagt K., Munn S., Tørsløv J., de Bruijn J. Alternative approaches can reduce the use of test animals under REACH. Addendum to the Report Assessment of Additional Testing Needs Under Reach. Effects of (Q)SARs, Risk-based Testing and Voluntary Industry Initiatives 2004, European Commission Joint Research Centre, Ispra, Italy, JRC Report EUR 21405 EN, 33 pp.
248. Van Hoof D., Dormeyer W., Braam S.R., Passier R., Monshouwer-Kloots J., Ward-van Oostwaard D., et al. Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. J Proteome Res 2010, 9(3):1610-1618.
249. Vescovi A.L., Parati E.A., Gritti A., Poulin P., Ferrario M., Wanke E., et al. Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Experimental Neurology 1999, 156(1):71-83.
250. Vierbuchen T., Wernig M. Direct lineage conversions: unnatural but useful?. Nature Biotechnology 2011, 29(10):892-907.
251. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Sudhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463(7284):1035-1041.
252. Vittet D., Prandini M.H., Berthier R., Schweitzer A., Martin-Sisteron H., Uzan G., et al. Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. Blood 1996, 88(9):3424-3431.
253. Weinshilboum R.M. Human biochemical genetics of plasma dopamine-beta-hydroxylase and erythrocyte catechol-o-methyltransferase. Human genetics Supplement 1978, 1:101-112.
254. Wilffert B., Swen J., Mulder H., Touw D., Maitland-Van der Zee A.H., Deneer V. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. International Journal of Clinical Pharmcology 2011, 33(1):3-9.
255. Wobus A.M., Boheler K.R. Embryonic stem cells: prospects for developmental biology and cell therapy. Physiological Reviews 2005, 85(2):635-678.
256. Wobus A., Löser P. Present state and future perspectives of using pluripotent stem cells in toxicology research. Archives of Toxicology 2011, 85(2):79-117.
257. Wobus A.M., Loser P. Present state and future perspectives of using pluripotent stem cells in toxicology research. Archives in Toxicology 2011, 85(2):79-117.
258. Wobus A.M., Guan K., Yang H.T., Boheler K.R. Embryonic stem cells as a model to study cardiac, skeletal muscle, and vascular smooth muscle cell differentiation. Methods in Molecular Biology 2002, 185:127-156.
259. Xu C., Police S., Rao N., Carpenter M.K. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circulation Research 2002, 91(6):501-508.
260. Xu C., Police S., Hassanipour M., Gold J.D. Cardiac bodies: a novel culture method for enrichment of cardiomyocytes derived from human embryonic stem cells. Stem Cells and Development 2006, 15(5):631-639.
261. Xu X.Q., Graichen R., Soo S.Y., Balakrishnan T., Rahmat S.N., Sieh S., et al. Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation 2008, 76(9):958-970.
262. Xu X.Q., Zweigerdt R., Soo S.Y., Ngoh Z.X., Tham S.C., Wang S.T., et al. Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy 2008, 10(4):376-389.
263. Xu M., Yan C., Tian Y., Yuan X., Shen X. Effects of low level of methylmercury on proliferation of cortical progenitor cells. Brain Research 2010, 1359:272-280.
264. Yang L., Soonpaa M.H., Adler E.D., Roepke T.K., Kattman S.J., Kennedy M., et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008, 453(7194):524-528.
265. Yarbro J.W. Mechanism of action of hydroxyurea. Seminars in Oncology 1992, 19(3 Suppl. 9):1-10.
266. Yildirimman R., Brolen G., Vilardell M., Eriksson G., Synnergren J., Gmuender H., et al. Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicological Sciences 2011, 124(2):278-290.
267. Yla-Outinen L., Heikkila J., Skottman H., Suuronen R., Aanismaa R., Narkilahti S. Human cell-based micro electrode array platform for studying neurotoxicity. Front Neuroeng 2010, vol. 3.
268. Yokoo N., Baba S., Kaichi S., Niwa A., Mima T., Doi H., et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochemical and Biophysical Research Communications 2009, 387(3):482-488.
269. Yoshida Y., Yamanaka S. iPS cells: a source of cardiac regeneration. The Journal of Molecular and Cellular Cardiology 2011, 50(2):327-332.
270. Yusa K., Rashid S.T., Strick-Marchand H., Varela I., Liu P.-Q., Paschon D.E., et al. Targeted gene correction of [agr]1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011, 478(7369):391-394.
271. Zeng X., Chen J., Deng X., Liu Y., Rao M.S., Cadet J.L., et al. An in vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP+ toxicity and GDNF neuroprotection. Neuropsychopharmacology 2006, 31(12):2708-2715.
272. Zeng H., Park J.W., Guo M., Lin G., Crandall L., Compton T., et al. Lack of ABCG2 expression and side population properties in human pluripotent stem cells. Stem Cells 2009, 27(10):2435-2445.
273. Zhang R., Su B. Small but influential: the role of microRNAs on gene regulatory network and 3'UTR evolution. Journal of Genetics and Genomics 2009, 36(1):1-6.
274. Zhang S.C., Wernig M., Duncan I.D., Brustle O., Thomson J.A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nature Biotechnology 2001, 19(12):1129-1133.
275. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research 2009, 104(4):e30-41.
276. Zhao D., Chen S., Cai J., Guo Y., Song Z., Che J., et al. Derivation and characterization of hepatic progenitor cells from human embryonic stem cells. PLoS ONE 2009, 4(7).
277. Zhu M.X., Zhao J.Y., Chen G.A., Guan L. Early embryonic sensitivity to cyclophosphamide in cardiac differentiation from human embryonic stem cells. Cell Biology International 2011, 35(9):927-938.
278. Zimmer B., Kuegler P.B., Baudis B., Genewsky A., Tanavde V., Koh W., et al. Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. Cell Death & Differentiation 2011, 18(3):383-395.
279. Zinchenko Y.S., Culberson C.R., Coger R.N. Contribution of non-parenchymal cells to the performance of micropatterned hepatocytes. Tissue Engineering 2006, 12(8):2241-2251.